Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-576-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:Falsified medicinal products (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20110215.29.2-576-000"2
lpv:hasSubsequent	lp_eu:2011-02-15-Speech-2-577-0002
lpv:speaker	lp:Oreste Rossi2
lpv:spokenAs	member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2012-02-01)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; BUDG (2009-10-07--2012-01-18)3 substitute; IMCO (2009-07-16--2012-01-18)3 unknown; Lega Nord (2009-07-14--2013-03-14)3 member; Delegation for relations with Japan (2009-09-16--2012-02-14)3 member; EFD (2009-07-14--2013-06-11)3
lpv:translated text	"Madam President, ladies and gentlemen, although the Commission’s proposed changes to the directive on medicinal products for human use are designed to help prevent the entry of falsified medicinal products, we would have expected more concrete results, particularly through the introduction of compulsory inspections of production sites in which active substances are manufactured in third countries. That option was rejected on the grounds that such checks would be too costly. The fact is that European companies have to meet extremely high quality standards, whereas companies manufacturing in other parts of the world do not. We are voting in favour, however, since measures are being introduced to make sure that imported pharmaceutical products are safer, including traceability, a ban on repackaging, compliance with EU safety standards, the partial regulation of Internet sales, and the possibility of extending similar measures to over-the-counter medicinal products as well."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph